drugset / Trial / NCT06490107
Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC
Phase 2
Active not recruiting
40 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
AstraZeneca · collab
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to assess the efficacy and safety of durvalumab combined with S-1 as adjuvant therapy of resectable Biliary Tract Cancer(BTC) with high risk of recurrence
Timeline
- Start
- 2024-05-24
- Primary completion
- 2026-12-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | S-1 | Small molecule | 40 mg/m2 | — |